W
The startup has developed a wound debridement technology that effectively targets and removes necrotic tissue, including fibrin, elastin, and collagen, from chronic wounds. This approach enhances clinical outcomes by improving wound care quality and reducing associated healthcare costs.
Updated 3 months ago
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup has developed a wound debridement technology that effectively targets and removes necrotic tissue, including fibrin, elastin, and collagen, from chronic wounds. This approach enhances clinical outcomes by improving wound care quality and reducing associated healthcare costs.